Suppr超能文献

血管内皮生长因子的表达与人类乳腺癌中的突变型p53及不良预后相关。

The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer.

作者信息

Linderholm B K, Lindahl T, Holmberg L, Klaar S, Lennerstrand J, Henriksson R, Bergh J

机构信息

Department of Oncology, Radiumhemmet, Karolinska Institute and Hospital, Stockholm, Sweden.

出版信息

Cancer Res. 2001 Mar 1;61(5):2256-60.

Abstract

Wild-type p53 protein has been shown to inhibit angiogenesis through thrombospondin in the preclinical setting. Here, we determined the associations between the expression of the angiogenic factor vascular endothelial growth factor (VEGF) and the p53 status, including different mutation sites and types, in primary breast cancer. Cytosols from 224 primary breast cancer patients were analyzed with an enzyme immunoassay for determination of human VEGF165 protein content. p53 status was determined by cDNA-based sequencing of the entire coding region, by immunohistochemistry (IHC), and by a p53 luminometric immunoassay (LIA) method. Statistically significant associations was found between higher VEGF content and non-wild-type p53 status for all methods; sequence-based data (P = 0.0019), IHC data (P = 0.0068), and the LIA method (r = 0.427; P > 0.001). Highest VEGF values were detected in tumors with p53 insertions, deletions, and stop codon mutations (P = 0.0043). Combining p53 status and VEGF content resulted in additional prognostic information, relapse-free survival (RFS; P = 0.0377), overall survival (OS; P = 0.0319), and breast cancer corrected survival (BCCS; P = 0.0292). In multivariate analysis, the relative hazard increased when the VEGF data were added to the p53 status, with a relative hazard of 1.7 for RFS and 3.0 for BCCS, compared with 1.1 for RFS and 1.4 for BCCS among the patients with either high VEGF content or p53 mutation. Higher VEGF content was statistically significantly correlated with a worse outcome for patients with estrogen receptor-positive tumors receiving adjuvant tamoxifen: RFS (P = 0.0471), OS (P = 0.0134), BCCS (P = 0.0064), as well as in multivariate analysis with point estimates of 3.4 and 2.1 for BCCS and RFS, respectively. VEGF expression is related to p53 status in human breast cancer patients. Combining VEGF with p53 status resulted in better prognostic prediction.

摘要

在临床前研究中,野生型p53蛋白已被证明可通过血小板反应蛋白抑制血管生成。在此,我们确定了原发性乳腺癌中血管生成因子血管内皮生长因子(VEGF)的表达与p53状态之间的关联,包括不同的突变位点和类型。采用酶免疫分析法对224例原发性乳腺癌患者的细胞溶质进行分析,以测定人VEGF165蛋白含量。通过对整个编码区进行基于cDNA的测序、免疫组织化学(IHC)和p53荧光免疫分析(LIA)方法来确定p53状态。所有方法均发现VEGF含量升高与非野生型p53状态之间存在统计学显著关联;基于序列的数据(P = 0.0019)、IHC数据(P = 0.0068)和LIA方法(r = 0.427;P > 0.001)。在p53插入、缺失和终止密码子突变的肿瘤中检测到最高的VEGF值(P = 0.0043)。结合p53状态和VEGF含量可提供额外的预后信息,无复发生存期(RFS;P = 0.0377)、总生存期(OS;P = 0.0319)和乳腺癌校正生存期(BCCS;P = 0.0292)。在多变量分析中,当将VEGF数据添加到p53状态时,相对风险增加,RFS的相对风险为1.7,BCCS的相对风险为3.0,而VEGF含量高或p53突变患者中RFS的相对风险为1.1,BCCS的相对风险为1.4。对于接受辅助他莫昔芬治疗的雌激素受体阳性肿瘤患者,较高的VEGF含量与较差的预后在统计学上显著相关:RFS(P = 0.0471)、OS(P = 0.0134)、BCCS(P = 0.0064),在多变量分析中,BCCS和RFS的点估计值分别为3.4和2.1。VEGF表达与人类乳腺癌患者的p53状态相关。将VEGF与p53状态相结合可实现更好的预后预测。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验